HomeOrderingContact UsAbout UsInvestor InformationSite Map

Executive Management

Craig Tuttle - Chief Executive Officer, President

Craig J. Tuttle has served as President and Chief Executive Officer of Transgenomic since July 2006. Mr. Tuttle was previously the President and COO of Duke Scientific, a specialty particle technology company, and before that he was the President and CEO of Applied Biotech, Inc, a leading point-of-care rapid diagnostics manufacturer in the Apogent Technologies group. He has held management positions at Seradyn, Boehringer Mannheim, Difco Laboratories and Cetus Corporation. Mr. Tuttle holds a B.S. degree in Biochemistry from UCLA, an M.S. degree in Biochemistry from the University of Colorado, and an MBA from St. Mary’s College.

 Top of Page
Chad Richards - Chief Commercial Officer

Mr. Richards joined Transgenomic in October 2007 as Senior Vice President, Sales and Marketing. Mr. Richards brings 14 years of sales and marketing experience in laboratory services and diagnostics. Before joining Trangenomic, Mr. Richards was the National Sales Director for Anatomic Pathology for Quest Diagnostics, the world’s largest laboratory service business. During his career with Quest Diagnostics, Mr. Richards held a variety of sales management roles in both their physician and hospital business segments. Before joining Quest Diagnostics, Mr. Richards held different marketing and sales management roles with Ventana Medical Systems, a world leader in developing and manufacturing immunohistochemistry and in-situ hybridization instruments and reagent systems. Mr. Richards holds a B.S. degree in Biology from the University of Minnesota.

 Top of Page
Brett Frevert - Chief Financial Officer

Mr. Frevert joined Transgenomic in June 2010 bringing nearly 25 years of financial leadership within a number of industries. Before joining Trangenomic, he served as CFO of a renewable fuels registrant, a commercial real estate entity, a commercial finance company, and an international credit card processing entity. Mr. Frevert has been involved in M&A transactions for the majority of his career and has participated in a numerous capital transactions totaling over $1.5 billion. He started his career with Deloitte where he primarily served large multinational publicly traded clients. Mr. Frevert holds a B.S. degree in Business Administration/Accounting from Wayne State College.

 Top of Page
Katrina Fahlin - Vice President of Quality

Katrina Fahlin is the Vice President of Quality for Transgenomic. She holds a B.S. degree in Professional Chemistry from South Dakota State University and has graduate work in chemistry from the University of Nebraska. Ms. Fahlin has more than 30 years of experience in the quality arena including thirteen years with Novartis in Quality Assurance. She is a qualified Lead Auditor and her regulatory experience includes ISO standards, and FDA experience with pharmaceuticals, feed, food, and food and feed additives. She has lead the successful efforts at Transgenomic to attain ISO 9001 certification for their instrument and bioconsumable business and the College of American Pathologist accreditation of the CLIA reference laboratory.

 Top of Page
Katherine A. Richardson, Ph. D. - Vice President of Research and Development

Dr. Richardson is Technical Director for Laboratory Services. She holds an S.B. degree in life sciences from the Massachusetts Institute of Technology and a Ph.D. in molecular cellular developmental biology from Iowa State University. Dr. Richardson has more than 25 years of molecular biology laboratory experience. She joins Transgenomic following eight years as a scientist with OSI Pharmaceuticals, where she specialized in molecular biology research and development in the area of oncology. Previously Dr. Richardson was with Eli Lilly and Company for nine years as a senior toxicologist specializing in genetic toxicology and molecular carcinogenesis. Dr. Richardson has to her credit nearly 60 publications, abstracts and presentations at scientific conferences, and she was part of the group at Eli Lilly that identified the link between the BRCA-1 gene and hereditary breast cancer.

 Top of Page
Contact WebmasterSend Page To ColleaguePrintable PageChange Country United States
Copyright © 1997-2012 Transgenomic, Inc., All Rights Reserved.the power of discovery™